CagriSema Achieves 23% Weight Loss But Falls Short of Zepbound Expectations

What Is CagriSema and How Does It Work?

CagriSema is Novo Nordisk's next-generation obesity therapy that combines two active ingredients in a single once-weekly subcutaneous injection: semaglutide 2.4 mg (the same active ingredient in Wegovy and Ozempic) and cagrilintide 2.4 mg, a long-acting analog of the pancreatic hormone amylin. The combination targets two complementary pathways involved in appetite regulation and energy balance, with the goal of achieving greater weight loss than either component alone.

Semaglutide is a GLP-1 receptor agonist that reduces appetite by mimicking the incretin hormone GLP-1, acting on the hypothalamus and brainstem to promote satiety, slow gastric emptying, and reduce food reward signaling. Cagrilintide is a long-acting amylin receptor agonist. Amylin is a peptide co-secreted with insulin by pancreatic beta cells that acts on the area postrema in the brainstem to reduce food intake, slow gastric emptying, and suppress glucagon secretion. The two hormones regulate appetite through overlapping but distinct neural circuits, providing a rationale for combination therapy.

Phase 2 data published in The Lancet in 2023 showed that the combination achieved approximately 15.6% weight loss over 32 weeks, outperforming semaglutide alone and cagrilintide alone. This generated significant excitement and analyst expectations that Phase 3 results, with longer treatment duration and optimized dosing, would reach 25% or higher — which would have clearly differentiated CagriSema from both Wegovy (approximately 15%) and Zepbound (approximately 22.5%).

What Did the REDEFINE-1 Trial Results Show?

The REDEFINE-1 trial, a Phase 3 randomized, double-blind study, enrolled approximately 3,400 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity) without diabetes. Participants were randomized to CagriSema, semaglutide 2.4 mg alone, or placebo, all administered as once-weekly subcutaneous injections for 68 weeks. The primary endpoints were percentage change in body weight and proportion of participants achieving ≥5% weight loss versus placebo.

At week 68, CagriSema achieved a mean body weight reduction of approximately 22.7% from baseline, compared to approximately 16% for semaglutide alone and approximately 2% for placebo. A majority of CagriSema participants achieved ≥10% weight loss, and a substantial proportion achieved ≥20% or more. The separation between CagriSema and semaglutide alone (approximately 6–7 percentage points) confirmed the additive benefit of cagrilintide.

However, the headline figure disappointed financial analysts and investors who had expected 25–27% based on extrapolations from Phase 2 data and the longer treatment period. Critically, the result provides only a marginal advantage over tirzepatide's 22.5% in SURMOUNT-1, a difference that is not considered clinically meaningful in the absence of a head-to-head trial. Novo Nordisk's stock fell over 20% following the announcement, wiping tens of billions of dollars from its market capitalization. The competitive dynamics in the obesity drug market — projected to reach substantial annual revenue by 2030 — now appear more balanced than previously expected.

How Does CagriSema Compare to Zepbound?

Direct comparison of CagriSema and tirzepatide (marketed as Zepbound for obesity and Mounjaro for diabetes) is complicated by differences in trial design, patient populations, and endpoints. In SURMOUNT-1, tirzepatide at its highest dose (15 mg weekly) achieved 22.5% weight loss at 72 weeks. CagriSema achieved approximately 22.7% at 68 weeks. While the numerical difference appears to favor CagriSema, the confidence intervals likely overlap, and cross-trial comparisons are inherently unreliable. A head-to-head superiority trial would be needed to determine which drug is truly more effective.

Side effect profiles show some differences. CagriSema's most common adverse events were gastrointestinal, including nausea, vomiting, diarrhea, and constipation, at rates generally higher than for semaglutide alone, likely reflecting the additive gastrointestinal effects of the amylin component. The treatment discontinuation rate due to adverse events was also higher for CagriSema than for semaglutide alone. Tirzepatide's gastrointestinal side effects were reported at broadly similar rates in SURMOUNT-1, with nausea affecting roughly one-third of participants on the highest dose and a treatment discontinuation rate of approximately 6%.

Practically, the competitive landscape will be shaped by supply, pricing, and insurance coverage. Both Novo Nordisk and Eli Lilly have faced massive supply constraints for their existing weight loss drugs. CagriSema's FDA approval timeline depends on ongoing regulatory review. Eli Lilly, meanwhile, has been developing an oral formulation of tirzepatide, which could represent a significant convenience advantage by eliminating the need for injections. Novo Nordisk is also advancing an oral formulation of semaglutide at higher doses, with Phase 3 data from the OASIS program showing meaningful weight loss. The obesity drug market is evolving rapidly, and patients will ultimately benefit from having multiple effective options.